The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00464997|
Recruitment Status : Unknown
Verified April 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : April 24, 2007
Last Update Posted : April 24, 2007
|Condition or disease|
Thirty Rheumatoid Arthritis patients currently treated with low dose methotrexate (MTX) will participate in this study. On the day of intake of methotrexate, the patients will receive 10 mg of MTX. Serum levels of MTX will be measured at time 0,30 ,90, 120 minutes, and after 12 and 24 hours.
Two weeks later, the patients will be recommended to take 100 mg aspirin/d during a week. The levels of MTX will be measured after a week of treatment in a way similar to a week before.
|Study Type :||Observational|
|Enrollment :||30 participants|
|Observational Model:||Defined Population|
|Official Title:||The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate|
|Study Start Date :||June 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00464997
|Principal Investigator:||Ori Elkayam, M.D||Tel Aviv Medical Center|